Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study

Part of paid clinical trials in Wilmington, North Carolina.

Sponsor
argenx
Study ID
NCT07264426
Status
Recruiting
Apply to this trial

Conditions

  • CIDP
  • CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)
  • Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Efgartigimod PH20 SC — BIOLOGICAL
    Efgartigimod treatment per country-specific label for the treatment of CIDP

Study Details

The aims of this study are to assess the real-world effectiveness of efgartigimod in treating chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), describe the "treatment journey" of participants with CIDP, and assess the utilization of health care services among adult participants with CIDP who initiate treatment with efgartigimod. As this is a noninterventional study, treatment choices and decisions will be left to the discretion of participants and their physicians, according to the standard of care. Each participant will be prospectively followed for up to 2 years from the date of initial administration of efgartigimod.

Key Dates

Start date
Aug 11, 2025
Status verified
Apr 2026
Primary completion
Oct 31, 2029
Completion
Oct 31, 2029

Study Design

Enrollment
200 participants (estimated)

Primary Outcome Measure

Change in aINCAT score over time [ Time Frame: Up to 2 years and 3 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
PPD VirtualWilmingtonNorth Carolina28401
Neil Brett, MD
[email protected]
857-350-4834

Find similar trials in Wilmington, NC

By research site
PPD Virtual· Wilmington, NC

Related Studies